Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 79.02 USD | +1.24% | +1.76% | -7.96% | |
| Dec. 06 | Transgene: new CFO, share price rises | CF |
| Dec. 04 | IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer | MT |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
78.05USD
Average target price
90.39USD
Spread / Average Target
+15.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.96% | 97 254 M $ | |
| +63.47% | 529 B $ | |
| +42.56% | 430 B $ | |
| -12.58% | 374 B $ | |
| -6.49% | 263 B $ | |
| -7.63% | 261 B $ | |
| +1.35% | 198 B $ | |
| -9.77% | 197 B $ | |
| -43.83% | 162 B $ | |
| +2.47% | 145 B $ |
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- News Gilead Sciences, Inc.
- Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $80 From $85, Maintains Neutral Rating
